JP2023515322A5 - - Google Patents

Info

Publication number
JP2023515322A5
JP2023515322A5 JP2022545967A JP2022545967A JP2023515322A5 JP 2023515322 A5 JP2023515322 A5 JP 2023515322A5 JP 2022545967 A JP2022545967 A JP 2022545967A JP 2022545967 A JP2022545967 A JP 2022545967A JP 2023515322 A5 JP2023515322 A5 JP 2023515322A5
Authority
JP
Japan
Application number
JP2022545967A
Other languages
Japanese (ja)
Other versions
JP7777872B2 (ja
JPWO2021173193A5 (https=
JP2023515322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059368 external-priority patent/WO2021173193A1/en
Publication of JP2023515322A publication Critical patent/JP2023515322A/ja
Publication of JP2023515322A5 publication Critical patent/JP2023515322A5/ja
Publication of JPWO2021173193A5 publication Critical patent/JPWO2021173193A5/ja
Priority to JP2025190141A priority Critical patent/JP2026041745A/ja
Application granted granted Critical
Publication of JP7777872B2 publication Critical patent/JP7777872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022545967A 2020-02-24 2020-11-06 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用 Active JP7777872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025190141A JP2026041745A (ja) 2020-02-24 2025-11-11 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980885P 2020-02-24 2020-02-24
US62/980,885 2020-02-24
PCT/US2020/059368 WO2021173193A1 (en) 2020-02-24 2020-11-06 Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025190141A Division JP2026041745A (ja) 2020-02-24 2025-11-11 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用

Publications (4)

Publication Number Publication Date
JP2023515322A JP2023515322A (ja) 2023-04-13
JP2023515322A5 true JP2023515322A5 (https=) 2023-11-10
JPWO2021173193A5 JPWO2021173193A5 (https=) 2023-11-10
JP7777872B2 JP7777872B2 (ja) 2025-12-01

Family

ID=77492116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545967A Active JP7777872B2 (ja) 2020-02-24 2020-11-06 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用
JP2025190141A Pending JP2026041745A (ja) 2020-02-24 2025-11-11 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025190141A Pending JP2026041745A (ja) 2020-02-24 2025-11-11 細胞ベースの治療を脳にホーミング、ブロック及び送達するための脳特異的抗原の使用

Country Status (7)

Country Link
US (1) US20230055337A1 (https=)
EP (1) EP4110354A4 (https=)
JP (2) JP7777872B2 (https=)
CN (1) CN115151268A (https=)
AU (1) AU2020431140A1 (https=)
CA (1) CA3170412A1 (https=)
WO (1) WO2021173193A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121414A1 (en) * 2022-12-08 2024-06-13 Université De Genève Chimeric antigen receptor
WO2025054259A1 (en) * 2023-09-08 2025-03-13 The Regents Of The University Of California Guiding development using self-assembling cells
CN119306836B (zh) * 2024-10-14 2025-07-11 中国人民解放军陆军军医大学第一附属医院 抗ptprz1嵌合抗原受体巨噬细胞在肺癌治疗中的应用
CN119286939B (zh) * 2024-11-15 2025-05-02 广东君厚生物医药有限公司 PSR.Syn.CD19.BCMA CAR-T细胞的制备方法及其细胞和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0813621A2 (pt) 2007-07-27 2017-05-09 Immatics Biotechnologies Gmbh imunoterapia contra tumores neuronais e cerebrais
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
AU2011323784A1 (en) * 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US20170107578A1 (en) 2014-03-21 2017-04-20 The Translational Genomics Research Institute Compositions, methods and kits for characterizing and screening for small cell ovarian carcinoma
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
WO2017193059A1 (en) * 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells
EP3560955A4 (en) 2016-12-26 2020-12-23 Kyowa Kirin Co., Ltd. ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN
KR20200071740A (ko) * 2017-09-28 2020-06-19 임팩트-바이오 리미티드. 저해성 키메라 항원 수용체 (icar)를 제조하기 위한 보편적 플랫폼
CA3095757A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023515322A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023549079A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016551A2 (https=)